Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?

Karen S Slobod, Chris Coleclough, Scott A Brown, John Stambas, Xiaoyan Zhan, Sherri Surman, Bart G Jones, Amy Zirkel, Pamela J Freiden, Brita Brown, Robert Sealy, Mattia Bonsignori, Julia L Hurwitz, Karen S Slobod, Chris Coleclough, Scott A Brown, John Stambas, Xiaoyan Zhan, Sherri Surman, Bart G Jones, Amy Zirkel, Pamela J Freiden, Brita Brown, Robert Sealy, Mattia Bonsignori, Julia L Hurwitz

Abstract

Today, scientists are often encouraged to custom-design vaccines based on a particular country or clade. Here, we review the scientific literature and then suggest that the overwhelming endeavor to produce a unique vaccine for every world region or virus subtype may not be necessary.

References

    1. Perrin L, Kaiser L, Yerly S. Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis. 2003;3:22–27. doi: 10.1016/S1473-3099(03)00484-5.
    1. Delwart EL, Orton S, Parekh B, Dobbs T, Clark K, Busch MP. Two percent of HIV-positive U.S. blood donors are infected with non-subtype B strains. AIDS Res Hum Retroviruses. 2003;19:1065–1070. doi: 10.1089/088922203771881149.
    1. Anderson JP, Rodrigo AG, Learn GH, Madan A, Delahunty C, Coon M, et al. Testing the hypothesis of a recombinant origin of human immunodeficiency virus type 1 subtype E. J Virol. 2000;74:10752–10765. doi: 10.1128/JVI.74.22.10752-10765.2000.
    1. McClutchan FE, Carr JK, Murphy D, Piyasirisilp S, Gao F, Hahn B, et al. Precise mapping of recombination breakpoints suggests a common parent of two BC recombinant HIV type 1 strains circulating in China. AIDS Res Hum Retroviruses. 2002;18:1135–1140. doi: 10.1089/088922202320567879.
    1. Thomson MM, Perez-Alvarez L, Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis. 2002;2:461–471. doi: 10.1016/S1473-3099(02)00343-2.
    1. Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, Thomas R, et al. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses. 2003;19:133–144. doi: 10.1089/088922203762688649.
    1. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, et al. Diversity considerations in HIV-1 vaccine selection. Science. 2002;296:2354–2360. doi: 10.1126/science.1070441.
    1. Hanke T, Barnfield C, Wee EG, Agren L, Samuel RV, Larke N, et al. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol. 2003;84:361–368. doi: 10.1099/vir.0.18738-0.
    1. Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C, et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J Virol. 2002;76:5435–5451. doi: 10.1128/JVI.76.11.5435-5451.2002.
    1. Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nature Medicine. 2000;6:951–955. doi: 10.1038/79626.
    1. Agwale SM, Zeh C, Robbins KE, Odama L, Saekhou A, Edubio A, et al. Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials. Vaccine. 2002;20:2139.
    1. Cao H, Mani I, Vincent R, Mugerwa R, Mugyenyi P, Kanki P, et al. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. J Infect Dis. 2000;182:1350–1356. doi: 10.1086/315868.
    1. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol. 1996;70:427–444.
    1. Ferrantelli F, Kitabwalla M, Rasmussen RA, Cao C, Chou TC, Katinger H, et al. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies – implications for acquired immunodeficiency syndrome vaccine. J Infect Dis. 2004;189:71–74. doi: 10.1086/420833.
    1. D'Costa S, Slobod KS, Webster RG, White SW, Hurwitz JL. Structural features of HIV envelope defined by antibody escape mutant analysis. AIDS Res Hum Retroviruses. 2001;17:1205–1209. doi: 10.1089/088922201316912808.
    1. Zhan X, Slobod KS, Surman S, Brown SA, Lockey TD, Coleclough C, et al. Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein. J Virol. 2003;77:4231–4236. doi: 10.1128/JVI.77.7.4231-4236.2003.
    1. Gonzales MJ, Delwart E, Rhee SY, Tsui R, Zolopa AR, Taylor J, et al. Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis. 2003;188:397–405. doi: 10.1086/376534.
    1. Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A, et al. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol. 2004;78:94–103. doi: 10.1128/JVI.78.1.94-103.2004.
    1. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature. 2002;420:434–439. doi: 10.1038/nature01200.
    1. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992;258:1938–1941.
    1. Burns DPW, Desrosiers RC. Envelope sequence variation, neutralizing antibodies and primate lentivirus persistence. Curr Top Microbiol Immunol. 1994;188:185–219.
    1. Titti F, Sernicola L, Geraci A, Panzini G, Di Fabio S, Belli R, et al. Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J Gen Virol. 1997;78:2529–2539.
    1. Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, Hanson CV. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr. 1994;7:211–219.
    1. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100:4144–4149. doi: 10.1073/pnas.0630530100.
    1. Rencher SD, Slobod KS, Dawson D, Lockey TD, Hurwitz JL. Does the key to a successful HIV vaccine lie among the envelope sequences of infected individuals? Aids Res Hum Retroviruses. 1995;11:1131–1133.
    1. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA. 2002;287:606–611. doi: 10.1001/jama.287.5.606.
    1. Nyambi PN, Nadas A, Mbah HA, Burda S, Williams C, Gorny MK, et al. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol. 2000;74:10670–10680. doi: 10.1128/JVI.74.22.10670-10680.2000.
    1. Slobod KS, Lockey TD, Howlett N, Srinivas RV, Rencher SD, Freiden PJ, et al. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis. 2004;23:106–110. doi: 10.1007/s10096-003-1075-3.
    1. Hurwitz JL, Slobod KS, Lockey TD, Wang S, Chou T-HW, Lu S. Application of the polyvalent approach to HIV-1 vaccine development. Current Drug Targets-Infectious Disorders. 2005.
    1. Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B, et al. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine. 2005;23:2454–2464. doi: 10.1016/j.vaccine.2004.10.030.
    1. Zhan X, Slobod KS, Surman S, Brown SA, Coleclough C, Hurwitz JL. Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells. Vaccine. 2004;22:1206–1213. doi: 10.1016/j.vaccine.2003.09.028.
    1. Burnet FM. Poliomyelitis in the light of recent experimental work. Health Bulletin Department of Health-Victoria, Australia. 1945.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit